DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment/Status of Claims
Receipt of Arguments/Remarks filed on 06/18/2026 is acknowledged. Claims 5 and 12-16 were cancelled. Claims 1-3 and 34-36 were amended.
Claims 21-24 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 06/26/2024.
Claims 1-3,17-20 and 34-36 are under examination.
Withdrawn Rejections
Applicant’s arguments and amendments, see page 4, filed 06/18/2026, with respect to the 35 U.S.C. 112(b) rejection of claims 1-3,5,12-20 and 34-36 have been fully considered and are persuasive due to removing “preferentially”. The 35 U.S.C. 112(b) rejection of claims 1-3,5,12-20 and 34-36 has been withdrawn.
Maintained Rejections- Modified based on Amendment
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Written Description Rejection
Claims 1-3,17-20 and 34-36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Claims 1-3,17-20 and 34-36 encompass a large genera of Ubiquitin Conjugating Enzyme E2 K (UBE2K) inhibitors that are an antisense nucleic acid molecule, siRNA, or shRNA that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 and which treat pancreatic cancer or liver cancer, reduce proliferation of a pancreatic cancer cell or liver cancer cell in a human subject, and induce death of a pancreatic cancer cell or liver cancer cell in a human subject. The antisense nucleic acid molecules, siRNA or shRNA complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 encompass a large genus of nucleic acid inhibitors that have various sequences with the recited functions.
The state of the art only teaches a few known UBE2K inhibitors and their effect on cancer before the effective filing date. KR 20150016816, hereinafter “Gwangju” (Published 3 June 2015), and cited on an IDS teaches PC3 cells transfected with UbbsiRNA were subcutaneously administered to mouse xenograft models and that the growth of PC3 cell-derived tumors was inhibited by UBB knockdown, resulting in about 40% reduction in tumor volume and weight [0080]. Gwangju teaches the amount of Ub-binding enzyme, e.g., Ube2K/E2-25K to Ub was reduced by Ubb siRNA treatment [0069], and proliferation of PC3 and HepG2 hepatocellular carcinoma cells was inhibited using siRNA [0071-0072].
When claims 1-3,17-20 and 34-36 are analyzed in light of the specification, the instant invention encompasses a large genus of antisense nucleic acid molecule, siRNA and shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2. The specification discloses the human UEB2K nucleic acid sequence is provided as SEQ ID NO: 2 (page 18, lines 1-2). The specification contemplates that the present disclosure includes a nucleic acid (e.g. antisense, siRNA, shRNA, dsiRNA, etc.) that partially or fully inhibits the enzyme by reducing the expression and/or activity of the enzyme (page 19). The specification contemplates that the UBE2K inhibitor can act by any mechanism, by inhibiting the expression at the RNA or protein level or inhibiting the activity of UBE2K, and in some embodiments is a specific inhibitor of UBE2K and does not substantially reduce the expression or activity of other polypeptides other than UBE2K (page 19). The specification contemplates that nucleic acid UBE2K inhibitors may be single or double stranded nucleic acids having a complementary region of at least 15 nucleotides in length that are complementary to a target sequence in a cell (page 19). Single stranded nucleic acid therapeutics are described on page 25, including antisense nucleic acids, and double stranded nucleic acids such as dsRNA, siRNA and iRNA agents are described on page 26-27. The specification fails to identify any specific antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that result in treating pancreatic or liver cancer in a subject and therefore the structure required for the function of treating pancreatic or liver cancer is not shown.
In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. The examples disclose that UBE2K was transiently knocked down using siRNA in Miapaca2, HepG2, SKHEP1, Hep3B, MDAMB231, SKBR3, T47D and BT549 cells (Example 2, page 63), and that UBE2K siRNA mediated knockdown resulted in a 50% decrease in cell number in Miapaca2 pancreatic cancer cells, 30% decrease in cell number in SKHEP1 and HepG2 hepatocellular carcinoma cells, and no effect of the siRNA in the remaining 5 cancer cell lines (page 63; Table 4 page 64). Example 5, pages 68-69 disclose UBE2K knock-down with shRNA. However, no sequences of the siRNAs or shRNA for UBE2K knock-down are disclosed. The number of species disclosed by complete structure is not sufficient to provide written description support for the broad genus of antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that treat pancreatic or liver cancer, reduce proliferation of a pancreatic or liver cancer cell in a subject, and induce death of a pancreatic or liver cancer cell in a subject.
In the instant case, the specification does not disclose any antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors whose complete structure is disclosed. There is a lack of a complete or partial structure for the claimed genus of antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 with the function of treating pancreatic or liver cancer, reducing proliferation of a pancreatic or liver cancer cell in a subject, and inducing death of a pancreatic or liver cancer cell in a subject.
The specification fails to identify the core structure of the antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitor that is complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 that is required to achieve the claimed function. No other species of UBE2K nucleic acid inhibitors are identified or described by the state of the art or specification to provide a representative number of antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors for the genus. One of ordinary skill in the art could make siRNA and antisense oligonucleotides by aligning an oligomer to a region of UBE2K nucleotides of SEQ ID NO: 2 and reduce expression of the sequence, however this does not provide support that these sequences would result in the functions recited in the instant claims regarding treating, reducing proliferation of, and inducing death of a genus of pancreatic or liver cancer cells in a subject.
While the genus encompasses a large number of antisense, siRNA and shRNA’s and variants thereof that have the same activity of inhibiting UBE2K, thereby treating pancreatic or liver cancer, reducing proliferation of pancreatic or liver cancer cells and inducing death of pancreatic or liver cancer cells in a subject, UBE2K antisense nucleic acid molecules, siRNA and shRNA’s in kind and the genus encompass a large number of variants and molecules that have a different structure, and the specification does not describe an essential structure of a representative number of species of the large genus that result in the functions recited in the claims. The specification does not provide description for which species of antisense nucleic acid molecules, siRNA, or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 within the broad genus would or would not result in treating pancreatic or liver cancer, reducing proliferation of pancreatic or liver cancer cells and inducing death of pancreatic or liver cancer cells in a subject.
Regarding the wherein clause reciting the sequence of the human UBE2K mRNA transcript in the claims, MPEP 2163 says “For example, disclosure of an antigen fully characterized by its structure, formula, chemical name, physical properties, or deposit in a public depository does not, without more, provide an adequate written description of an antibody claimed by its binding affinity to that antigen, even when preparation of such an antibody is routine and conventional.” See Amgen Inc. v. Sanofi 872 F.3d 1367, 1378, 124 USPQ2d 1354, 1361 (Fed. Cir. 2017) cited in MPEP 2163. Similarly, the disclosure of SEQ ID NO: 2 as the human UBE2K nucleic acid sequence that the nucleic acid inhibitor is complementary to does not provide adequate written description for a UBE2K antisense nucleic acid molecule, siRNA or shRNA and that results the recited function.
Next, then, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics (i.e., other than nucleotide sequence), specific features and functional attributes that would distinguish different members of the claimed genus. In the instant case, the functional characteristics in claims 1-3 (treating pancreatic cancer or liver cancer, reducing proliferation of a pancreatic or liver cancer cell and inducing death of a pancreatic or liver cancer cell in a subject) are not coupled with a known structure. The specification fails to identify a core structure of the antisense nucleic acid molecule, siRNA or shRNA UB2EK inhibitor complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 necessary for treating pancreatic cancer or liver cancer, reducing proliferation of a pancreatic or liver cancer cell and inducing death of a pancreatic or liver cancer cell in a subject, as well as a partial structure, physical or chemical property, or functional characteristic coupled with a structure/function relationship responsible for treating pancreatic cancer or liver cancer, reducing proliferation of a pancreatic or liver cancer cell and inducing death of a pancreatic or liver cancer cell in a subject to demonstrate possession of the full invention as claimed at the time of filing.
Applicant’s attention is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, "Written Description" Requirement (MPEP2163).
In conclusion, Applicants disclosure of the target human UBE2K mRNA transcript of SEQ ID NO: 2 that the recited antisense nucleic acid molecule, siRNA or shRNA as the UBE2K inhibitor is complementary to is not deemed sufficient to reasonably convey to one skilled in the art that the instant disclosure was in possession of the claimed broad genus of antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 with the function of treating pancreatic cancer or liver cancer, reducing proliferation of a pancreatic or liver cancer cell and inducing death of a pancreatic or liver cancer cell in a subject in need thereof at the time the application was filed. Thus, it is concluded that the written description requirement is not satisfied for the claimed genus.
Response to Arguments
Applicant's arguments, filed 06/18/2025, have been fully considered but they are not persuasive.
Applicant cites MPEP 2163 II A3(a)(ii) on pages 5-6, and restates what amended claims 1-3 recite. Applicant states that the claims as currently amended do not recite that the UBE2K inhibition preferentially inhibits UBE2K as compared to other E2 proteins and therefore the comments regarding this limitation are not applicable to the claims as currently amended, as well as that claims 1-3 have been amended to limit the cancer to pancreatic cancer or liver cancer and the cancer cell to a pancreatic cancer cell or liver cancer cell, and have been amended to require that the UBE2K inhibitor is an antisense nucleic acid molecule, siRNA, or shRNA that is complementary to a human UBE2K mRNA transcript encoded by the nucleic acid sequence of SEQ ID NO: 2.
Applicant argues on page 7 that the specification describes a broad range of nucleic acid UBE2K inhibitors include single stranded nucleic acids such as antisense nucleic acids, double stranded nucleic acids such as double stranded RNA molecules, e.g., siRNAs (pages 20-27). Applicant argues that the specification teaches that nucleic acid inhibitors include both single and double stranded nucleic acids (i.e., nucleic acids having a complementarity region of at least 15 nucleotides in length) that are complementary to a target sequence in a cell (page 20, lines 23-26), and the specification teaches that antisense nucleic acid therapeutic agents are single stranded nucleic acids, typically about 16-30 nt in length, and are complementary to a target nucleic acid sequence in a target cell (page 25, lines 18-20) and teaches that antisense RNA molecule may have about 15-30 nt that are complementary to the target mRNA and the antisense RNA molecule may have a sequence of at least 15,16,17,18,19,20 or more contiguous nucleotides that are complementary to the target mRNA (page 25, lines 25-28). Applicant argues the specification provides the human UBE2K nucleic acid sequence as SEQ ID NO: 2 (page 18, lines 1-2) and since the specification teaches that nucleic acid inhibitors are complementary to a target sequence and provides the target sequence and discloses exemplary lengths for the nucleic acid UBE2K inhibitors, a person of ordinary skill in the art could envision the complete structure of exemplary nucleic acid UBE2K inhibitors for use in the presently claimed methods.
This is not found persuasive. While Applicant’s have amended the claims to narrow the genus of cancer and does further narrow the genus of UBE2K nucleic acid inhibitors that are complementary to SEQ ID NO: 2 to antisense, siRNA or shRNA, the claims still recite a method of using a large genus of antisense nucleic acid molecules, siRNA or shRNA complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 and which result in the recited functions. It is also noted that while the claims recite the human UBE2K target sequence is SEQ ID NO: 2, the claims do not recite how many nucleotides of the antisense nucleic acid molecule, siRNA or shRNA are complementary to SEQ ID NO: 2 to perform the recited functions. Regarding MPEP 2163 II A3(a)(ii), the specification has not provided sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by the disclosure of relevant, identifying characteristics (i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics). Disclosure of the nucleic acid inhibitors as being single or double stranded, the range in nucleotide length and reciting that they are complementary to a target mRNA and providing the human UBE2K nucleic acid sequence as SEQ ID NO: 2 does not provide a disclosed correlation between structure and function. This does not describe the required structure of the recited UBE2K inhibitors which results in treating pancreatic or liver cancer, reducing proliferation of a pancreatic or liver cancer cell or inducing cell death of a pancreatic or liver cancer cell in a human subject in need thereof. The antisense nucleic acid molecules, siRNA or shRNA UBE2K inhibitors provided by the instant specification could bind and target different portions of the human UBE2K nucleic acid sequence of SEQ ID NO: 2 and as stated above there is no recitation of the required number of nucleotides that the inhibitor is complementary to in regards to SEQ ID NO: 2, and therefore encompasses many possible sequences, and one would not be able to determine the essential structure of the different nucleic acid UBE2K inhibitors that results in treating pancreatic or liver cancer, reducing proliferation of a pancreatic or liver cancer cell or inducing cell death of a pancreatic or liver cancer cell in a human subject in need thereof.
Applicant cites MPEP 2163 II A 3(a)(C)(1) on pages 7-8 and that the specification describes a representative number of species of the UBE2K inhibitors recited in the claims as amended and therefore provides adequate written description.
This is not found persuasive. Regarding MPEP 2163 II A 3(a)(C)(1), the specification does not identify the required structure of any nucleic acid UBE2K inhibitors that is capable of carrying out the recited function to provide a structure-function correlation. As cited in the written description rejection, “For example, disclosure of an antigen fully characterized by its structure, formula, chemical name, physical properties, or deposit in a public depository does not, without more, provide an adequate written description of an antibody claimed by its binding affinity to that antigen, even when preparation of such an antibody is routine and conventional.” See Amgen Inc. v. Sanofi 872 F.3d 1367, 1378, 124 USPQ2d 1354, 1361 (Fed. Cir. 2017) cited in MPEP 2163. Therefore, the disclosure of SEQ ID NO: 2 as the human UBE2K nucleic acid sequence, does not provide adequate written description of a UBE2K inhibitor which is an antisense nucleic acid molecule, siRNA or shRNA that is complementary to a human UBE2K mRNA transcript encoded by the nucleic acid sequence of SEQ ID NO: 2 and results in treating pancreatic cancer or liver cancer, reducing proliferation of and inducing death of a pancreatic cancer cell or a liver cancer cell. Applicant has provided the same arguments as last time, and did not respond to the Examiner’s response regarding how this is likened to Amgen Inc. v. Sanofi.
Therefore, the examiner is maintaining the 35 U.S.C. 112(a) Written description rejection.
Scope of Enablement Rejection
Claims 1-3,17-19 and 34-36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating pancreatic or liver cancer, reducing proliferation of, or inducing cell death in hepatocellular carcinoma or pancreatic cancer cells in a subject by direct administration of an UBE2K antisense oligonucleotide, siRNA, or shRNA complementary to SEQ ID NO: 2 to the site of the tumor, does not reasonably provide enablement for a method of treating pancreatic or liver cancer, reducing proliferation and inducing death of pancreatic or liver cells in a subject by administering antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2 by a genus of administration routes. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
As stated in MPEP §2164.01(a), “there are many factors to consider when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any experimentation is ‘undue’.” These factors include, but are not limited to:
1. The breadth of the claims;
2. The nature of the invention;
3. The state of the prior art;
4. The level of skill in the art;
5. The level of predictability in the art;
6. The amount of direction provided by the inventor;
7. The presence or absence of working examples;
8. The quantity of experimentation necessary needed to make or use the invention based on the disclosure.
The Breadth of the Claims and Nature of the Invention
Claims 1-3,17-19 and 34-36 encompass administering to a human subject in need thereof, antisense nucleic acid molecule, siRNA or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by SEQ ID NO: 2, that treat pancreatic or liver cancer, reduce proliferation of a pancreatic or liver cancer cell in a subject, and induce death of a pancreatic or liver cancer cell in a subject by any route of administration. Claims 17-19 read on the additional agent being a UBE2K inhibitor that is not enabled.
The State of the Prior Art
Before the effective filing date, the state of the art is limited regarding treating a cancer with a genus of UBE2K inhibitors which are antisense, siRNA or shRNA and are complementary to human UBE2K mRNA transcript of SEQ ID NO: 2. KR 20150016816, hereinafter “Gwangju” (Published 3 June 2015), and cited on an IDS, teaches PC3 cells transfected with UbbsiRNA were subcutaneously administered to mouse xenograft models and that the growth of PC3 cell-derived tumors was inhibited by UBB knockdown, resulting in about 40% reduction in tumor volume and weight [0080]. Gwangju teaches the amount of Ub-binding enzyme, e.g., Ube2K/E2-25K to Ub was reduced by Ubb siRNA treatment [0069], and proliferation of PC3 and HepG2 hepatocellular carcinoma cells was inhibited using siRNA [0071-0072].
Regarding nucleic acid based cancer therapeutics, MacLeod et al. (The Journal of Clinical Pharmacology 2017, 57(S10) S43-S59), teach that siRNA based therapeutics have great potential as cancer therapeutics, however many challenges remain, including rapid degradation, poor cellular uptake and off-target effects, but improvements in chemical modifications and nanocarriers have potential to make the translational process faster and more effective (page S52, right column). Regarding antisense oligonucleotides, MacLeod et al. teach Generation 2.0 ASOs have shown less potent effects in extrahepatic and extrarenal tissues that accumulate lower concentrations of these drugs, including skeletal muscle and tumors, and therefore the clinical experience with this generation of ASOs in cancer treatment has been and is still limited (page S53, right column). Macleod et al. teach Generation 2.5 ASOs which incorporates a constrained ethyl nucleoside modification significantly increases affinity for the target RNA and has increased potency in vitro and in vivo compared to Generation 2.0 ASOs, and increases the range of tissue in which potent antisense pharmacology can be achieved to include difficult to target tissues such as tumors and skeletal muscle (Page S54, left column). MacLeod et al. teach some key challenges remail with RNA therapeutics, including the ADME properties of either unformulated ASOs and miRNA therapeutics or nanoparticle encapsulated siRNAs are limited, and upon systemic delivery, these agents distribute broadly to most tissues, although the liver and kidney are the main target organism and tumors accumulate less. Uptake into tumor cells themselves and release of drug from endosomal compartments into the respective productive compartments (the nuclease for ASOs and miRNAs and the cytoplasm for siRNAs) also limit the maximal activity of these agents (Page S55, left column). MacLeod et al. teach the future of RNA therapeutics for cancer and that ideally can be selectively delivered to the tumor cells of interest with a targeted delivery moiety (Page S55, left column).
Regarding the route of administration, Dai et al. (J. Mater. Chem. B, 2016, 4, 6758-6772) teach that pharmaceutical preparations for tumor therapy are usually administered orally or by injection, however the drug will be either translocated systemically or rapidly removed from the body which leads to lower bioavailability of drugs and higher toxic side effects of the medication (pages 6759-6760). Dai et al. teach one strategy to address this is functionalization of targeting moieties to deliver the drug to the target site (page 6760). Dai et al. teach passive and active targeting drug delivery systems to overcome the disadvantages discussed above (page 6762-6764). Dai et al. teach that active targeting is achieved by attaching specific ligands/antibodies to the nanocarriers which recognize receptors or antigens on the tumor cell surfaces and improve uptake and enhance therapeutic efficacy of anticancer agents and reduce undesired side effects (page 6763, Section 3.2.1). Dai et al. teach there are several drug delivery systems that are in clinical trials using passive targeting to deliver therapeutics such as siRNA, CPT, PTX and SN38 to tumor sites with good antitumor activity (page 6767, Table 2) and preclinical studies using actively targeting drug delivery systems (page 6768, Table 3).
Therefore, the state of the art teaches siRNA that reduces UBE2K and proliferation of hepatocellular carcinoma cells, and that there are disadvantages to oral and intravenous injection of anti-cancer drugs for treating cancer that may affect the efficacy of treatment and that siRNA based therapeutics have great potential as cancer therapeutics but challenges include rapid degradation, poor cellular uptake and off-target effects and the need for chemical modification or an effective delivery system in order to reach or be taken up by the tumor. It is noted that the instant claims do not recite any specific type of administration route, delivery means or chemical modification of the nucleic acid active as described above in the art in order to enable delivery of the nucleic acid active to the affected tissue (pancreas or liver).
The Level of Predictability in the Art
The instant claimed invention is highly unpredictable due to the claims encompassing treating pancreatic or liver cancer, reducing proliferation and inducing death of pancreatic or liver cancer cells in a subject by administering a large genera of antisense nucleic acid, siRNA or shRNA UBE2K inhibitors that are complementary to a human UBE2K mRNA transcript encoded by the nucleic acid sequence of SEQ ID NO: 2 by any administration route. The large number of species encompassed by the genus of UBE2K inhibitors complementary to a human UBE2K mRNA transcript encoded by the nucleic acid sequence of SEQ ID NO: 2 and administration to the subject by any route, adds to the unpredictability of the claimed invention.
It is also noted that the instant claims do not recite that the UBE2K inhibitor has any chemical modifications or is part of a delivery system such as a nanoparticle or includes a targeting system to reach the cancer cells in the affected organ (pancreas or liver). This adds to the unpredictability that a nucleic acid inhibitor (antisense oligo, siRNA or shRNA) would be capable of reaching target pancreatic or liver cancer cells before being degraded and carry out the recited effect of treating pancreatic or liver cancer, reducing proliferation of cancer cells or inducing death of cancer cells.
It would be unpredictable that the nucleic acid UBE2K inhibitor can be administered to the subject by any route of administration, other than direct administration to the site of the tumor. For example, it would be unpredictable that oral administration of an antisense oligo, siRNA or shRNA would result in treatment of liver cancer, due to the drug being removed from the body, and would result in lower bioavailability.
If one skilled in the art cannot readily anticipate the effect of a change within the subject matter to which that claimed invention pertains (e.g., a method of treating pancreatic or liver cancer, a method of reducing proliferation of a pancreatic or liver cancer cell, a method of inducing death of a pancreatic or liver cancer cell in a subject in need thereof, the method comprising administering to the subject an antisense nucleic acid molecule, siRNA or shRNA complementary to SEQ ID NO: 2), then there is a lack of predictability in the art. The court has indicated that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. (See In re Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970)). This is because it is not obvious from the disclosure of one species, what other species will work.
The Amount of Direction Provided by the Inventor and
The Presence or Absence of Working Examples
Regarding claims 1-3,17-19 and 34-36, the specification does not enable any
person skilled in the art to which it pertains to make and/or use the invention
commensurate in scope with the claims. Claim 20 is not rejected as the recited
chemotherapeutic agents are well known agents that are known in the art to be
successful in treating various cancers.
The specification contemplates UBE2K nucleic acid inhibitors (e.g. antisense, siRNA, shRNA, dsiRNA, etc.) and contemplates a large genera of administration routes, including orally, parenterally, topically, inhalation, intravenous, intramuscular, subcutaneous, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injections or injection directly into the tumor (pages 5-6). The specification contemplates that the UBE2K inhibitor can act by any mechanism, by inhibiting the expression at the RNA or protein level or inhibiting the activity of UBE2K, and in some embodiments is a specific inhibitor of UBE2K and does not substantially reduce the expression or activity of other polypeptides other than UBE2K (page 19).
The examples disclose that UBE2K was transiently knocked down using siRNA in Miapaca2, HepG2, SKHEP1, Hep3B, MDAMB231, SKBR3, T47D and BT549 cells (Example 2, page 63), and that UBE2K siRNA mediated knockdown resulted in a 50% decrease in cell number in Miapaca2 pancreatic cancer cells, 30% decrease in cell number in SKHEP1 and HepG2 hepatocellular carcinoma cells, and no effect of the siRNA in the remaining 5 cancer cell lines (page 63; Table 4 page 64). Example 5, pages 68-69 disclose UBE2K knock-down with shRNA. Figure 16 shows confirmation of UBE2K knockdown in UBE2K shRNA transduced MiaPaca2 cell lines. No sequences of the siRNAs or shRNA for UBE2K knock-down are disclosed.
Therefore, as the examples disclose that UBE2K siRNA knockdown only resulted in a decreased cell number in pancreatic cancer cells and hepatocellular carcinoma cells, and no effect in the other 5 cancer cell lines and the state of the art teaches Ube2K/E2-25K to Ub was reduced by Ubb siRNA treatment and proliferation of HepG2 hepatocellular carcinoma cells was inhibited (Gwangju, paragraphs 0069,0071,0072), the instant claims are only enabled for treatment, reducing proliferation of, and inducing cell death of pancreatic cancer and hepatocellular carcinoma cells in a subject by direct administration. The specification and state of the art do not provide enablement for treating pancreatic or liver cancer, reducing proliferation of, or inducing cell death thereof in a subject by non-direct routes of administration.
The Quantity of Experimentation Necessary
Regarding claims 1-3,17-19 and 34-36, in light of the unpredictability surrounding the breadth of the claimed method, one wishing to practice the presently claimed invention would be unable to do so without engaging in undue experimentation. One of ordinary skill in the art would not be able to use the information provided by the instant specification to carry out the full scope of the invention as claimed. In absence of such information in the specification as well as the state of the art, a person of ordinary skill in the art would reasonably require an undue quantity of experimentation to practice the full scope of the claimed method.
Conclusion of 35 U.S.C. 112(a) (Enablement) Analysis
After applying the Wands factors and analysis to claims 1-3,17-19 and 34-36, in view of the applicant’s entire disclosure, it is concluded that the specification is not enabled for the full scope as discussed above.
Response to Arguments
Applicant's arguments filed 06/18/2026, have been fully considered but they are not persuasive.
Applicant cites In Re Marzocchii and Horton, 169 U.S.P.Q. 367 on page 10, which states “It is the Patent Office’s burden to present evidence that there is some reason to dispute the enablement provided in the specification”. Applicant argues that the test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation per MPEP 2164.01.
This is not found persuasive because the Examiner has evaluated and discussed each of the Wands factors as described in the Scope of Enablement rejection to determine whether there is sufficient evidence to determine if the disclosure does not satisfy the enablement requirement and whether experimentation is undue. The examiner has brought up numerous reasons for each of the Wands factors, that support the scope of enablement rejection. This includes the breadth of the claims which encompasses a genus of antisense, siRNA or shRNA UBE2K inhibitors complementary to SEQ ID NO: 2 and genus of administration routes and lack of chemical modification of the UBE2K inhibitor or an effective delivery system to reach the target cancer tissues/cells (pancreas or liver); the limited state of the art regarding antisense, siRNA or shRNA UBE2K inhibitors with the recited functions, the lack of guidance provided by the specification and absence of working examples regarding the genus of nucleic acid UBE2K inhibitors that can treat pancreatic or liver cancers by a genus of administration routes, which in turn supports the case for undue experimentation. Therefore, the examiner has determined based on evaluating each of the Wands factors, that in the absence of such information in the specification as well as the state of the art, a person of ordinary skill in the art would reasonably require an undue quantity of experimentation to practice the full scope of the claimed method.
Applicant argues on page 9 that the specification provides methods for identifying nucleic acid UBE2K inhibitors, and the specification provides methods of producing nucleic acid inhibitors on page 23, lines 1-4, and a person of ordinary skill in the art could prepare nucleic acid inhibitors that are complementary to SEQ ID NO: 2 using only routine experimentation. Applicant cites page 19, lines 25 through page 20 line 8 of the specification for methods for identifying nucleic acid inhibitors of UBE2K and that the person of ordinary skill in the art could prepare and identify a nucleic acid UBE2K antisense nucleic acid molecule, siRNA or shRNA complementary to SEQ ID NO: 2 based on the teachings in the specification.
This is not found persuasive because while the specification provides methods known in the art for identifying UBE2K inhibitors on page 19, one of ordinary skill in the art would not be able to use the information provided by the instant specification to carry out the full scope of the invention as claimed. While one of ordinary skill in the art could design and make antisense oligonucleotides, siRNA or shRNA’s based on knowing the target sequence of human UBE2K of SEQ ID NO: 2, this does not mean that the specification has shown how to use these to perform the recited functions. There is no instruction as to how to use a genus of UBE2K inhibitors which are antisense nucleic acid molecules, siRNA or shRNA complementary to human UBE2K of SEQ ID NO: 2 to treat, reduce proliferation of, and induce cell death in a pancreatic or liver cancer cells that would result in the claimed inhibitors reaching the desired target cells and tissues in a subject to result in the recited functions.
Applicant argues on page 10 that the specification provides working examples demonstrating use of nucleic acid UBE2K inhibitors for treatment of cancer, including Examples 2-4 that demonstrate the use of an siRNA UBE2K inhibitor for inhibiting growth of different cancer cell lines and demonstrate UBE2K inhibition was effective in reducing proliferation of pancreatic cancer and hepatocellular carcinoma cell lines, and Example 5 demonstrates using shRNA UBE2K inhibitor for reducing growth of pancreatic cancer cells, and therefore based on the teachings in the specification, a person of ordinary skill in the art could identify UBE2K inhibitors and use them in the treatment of cancer without undue experimentation. The specification teaches different modes of administration (pages 5,6) and methods of administering antisense nucleic acid molecules, siRNAs and shRNA are well known in the art and therefore suitable administration routes could be selected based on the teachings in the speciation and in the art using routine experimentation.
This is not found persuasive, because as described in the scope of enablement rejection, the specification and state of the art do not provide enablement for other means of administration other than direct administration to the site of the tumor. Therefore, the examiner concludes and maintains that the specification is not enabled for the full scope as claimed.
Conclusion
Claims 1-3,17-20 and 34-36 are rejected.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHANIE L SULLIVAN whose telephone number is (703)756-4671. The examiner can normally be reached Monday-Friday, 7:30-3:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ram R Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/STEPHANIE L SULLIVAN/Examiner, Art Unit 1635
/ABIGAIL VANHORN/Primary Examiner, Art Unit 1636